Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: Correlative analysis from a large North American cooperative group trial

Blood

Volumn 121, Issue 18, 2013, Pages 3547-3553

  Kanakry, Jennifer A ^a   Li, Hailun ^b   Gellert, Lan L ^c   Lemas, M Victor ^a   Hsieh, Wen Son ^d   Hong, Fangxin ^b   Tan, King L ^e   Gascoyne, Randy D ^e   Gordon, Leo I ^f   Fisher, Richard I ^g   Bartlett, Nancy L ^h   Stiff, Patrick ⁱ   Cheson, Bruce D ^j   Advani, Ranjana ^k   Miller, Thomas P ^l   Kahl, Brad S ^m   Horning, Sandra J ⁿ   Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h USA   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j GEORGETOWN UNIVERSITY   (United States)

^k STANFORD UNIVERSITY   (United States)

^l UNIVERSITY OF ARIZONA   (United States)

^m UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁿ GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; NUCLEIC ACID; VINBLASTINE; VIRUS DNA; CHLORMETHINE; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA EXTRACTION; EPSTEIN BARR VIRUS; FAILURE FREE SURVIVAL; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; ADJUVANT THERAPY; BLOOD; CONTROLLED CLINICAL TRIAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENETICS; MALE; MIDDLE AGED; NORTH AMERICA; PHYSIOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DNA, VIRAL; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; FEMALE; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOADJUVANT THERAPY; NORTH AMERICA; PREDNISONE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879750415     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-454694     Document Type: Article

References (26)

1. Ambinder RF, Browning PJ, Lorenzana I, et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood. 1993;81(2):462-467. (Pubitemid 23027165)
2. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375-382. (Pubitemid 27107262)
3. Jarrett RF, Stark GL, White J, et al Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood. 2005;106(7):2444- 2451. (Pubitemid 41510819)
4. Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer. 1990;46(5): 801-804.
5. Glaser SL, Gulley ML, Borowitz MJ, et al. Interand intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma. 2004;45(3):489-497. (Pubitemid 38196031)
6. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer. 1999;84(4):442-448. (Pubitemid 29337135)
7. Hohaus S, Santangelo R, Giachelia M, et al. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011;17(9):2885-2892.
8. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res. 2006;12(2):460-464. (Pubitemid 43166136)
9. Wagner HJ, Schläger F, Claviez A, et al. Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction. Eur J Cancer. 2001;37(15):1853-1857. (Pubitemid 32913311)
10. Musacchio JG, Carvalho MG, Morais JC, et al. Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease. Sao Paulo Med J. 2006;124(3):154-157.
11. Spacek M, Hubacek P, Markova J, et al. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients. APMIS. 2011;119(1):10-16.
12. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684-691.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63(9):2028-2032. (Pubitemid 36538602)
15. Ryan JL, Fan H, Swinnen LJ, et al. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol. 2004;13(2):61-68. (Pubitemid 38668140)
16. Ryan JL, Fan H, Glaser SL, et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn. 2004;6(4):378-385. (Pubitemid 39517407)
17. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24(34):5414-5418. (Pubitemid 46623174)
18. Lo YM, Leung SF, Chan LY, et al. Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann N Y Acad Sci. 2000;906:99-101. (Pubitemid 30255465)
19. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000;60(24):6878-6881. (Pubitemid 32059157)
20. Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243-249. (Pubitemid 38879864)
21. Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120(10):2003-2010.
22. Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999;59(21):5452-5455. (Pubitemid 29526455)
23. Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012;119(18):4129-4132.
24. Deau B, Bachy E, Ribrag V, et al. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma. 2013;54(1):41-45.
25. Barros MH, Hassan R, Niedobitek G. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res. 2012;18(14):3762- 3771.
26. Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012;120(16):3280-3287.